FindOwnerSearch
Brands and Their Owners
Welcome to the Brand page for “ORAMELT”, which is offered here for In the statement, lines 1-4 is deleted, and valeant international bermuda, clarendon house, 2 church street, hamilton hm11 (bermuda limited liability company) is inserted.;pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of huntington's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the treatment of depression, depressive disorders and mental illnesses; antidepressants; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of pain; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of cardiopulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of hypertension, angina, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of metabolic disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of diabetes; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of viral and infectious diseases; drug delivery agents consisting of rapidly dissolving compounds, formulations, compositions and agents that facilitate delivery of a wide range of human and veterinary pharmaceuticals; and drug delivery agents in the nature of pill coatings that facilitate delivery of a wide range of human and veterinary pharmaceuticals; pharmaceutical preparations and substances for the prevention, treatment, and alleviation of tourette syndrome;color is not claimed as a feature of the mark.;.
Its status is currently believed to be active. Its class is unavailable. “ORAMELT” is believed to be currently owned by “BAUSCH HEALTH IRELAND LIMITED”.
| Owner: |
BAUSCH HEALTH IRELAND LIMITED
Owner Details |
|---|---|
| Description: |
In the statement, Lines 1-4 is deleted, and Valeant International Bermuda, Clarendon House, 2 Church Street, Hamilton HM11 (Bermuda Limited Liability Company) is inserted.;Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the central nervous system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Parkinson's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Huntington's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of amyotrophic lateral sclerosis; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Alzheimer's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of epilepsy; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the treatment of depression, depressive disorders and mental illnesses; antidepressants; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of anxiety; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of pain; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the cardiovascular system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of cardiopulmonary disorders, diseases, conditions, and ailments; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of hypertension, angina, high blood pressure, heart failure and ventricular dysfunction; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of metabolic disorders, diseases, conditions, and ailments; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of diabetes; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of viral and infectious diseases; Drug delivery agents consisting of rapidly dissolving compounds, formulations, compositions and agents that facilitate delivery of a wide range of human and veterinary pharmaceuticals; and Drug delivery agents in the nature of pill coatings that facilitate delivery of a wide range of human and veterinary pharmaceuticals; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Tourette syndrome;Color is not claimed as a feature of the mark.;
|
| Categories: | STATEMENT |